The case for using novel value elements when assessing COVID-19 vaccines and therapeutics

23 June 2020 - In the span of mere weeks, the novel coronavirus (COVID-19) has upended modern life. Schools and businesses ...

Read more →

Proposed legislation to stabilise ACA threatens health care innovation

22 June 2020 - This week, the Democratic led House of Representatives may introduce legislation that seeks to stabilise the ...

Read more →

Drug innovation is back in fashion

21 May 2020 - Big pharma is no longer the villain. ...

Read more →

Big pharma has the chance to come to the world’s rescue

20 April 2020 - The pandemic may finally do for the pharmaceutical industry what relentless TV advertising cannot: show off its ...

Read more →

Australia's biotech innovations heading offshore, prompting calls for greater funding to bring them to market

11 February 2020 - The demand on the health sector has never been more evident, as the world scrambles to ...

Read more →

Supporting innovative medicines funding in Scotland

21 January 2020 - Scotland receives superb value from the latest medicines and vaccines thanks to robust measures which ensure ...

Read more →

After 20 years of using economic evaluation, should NICE be considered a methods innovator?

13 January 2020 - NICE is only one of several organisations internationally that uses economic evaluation as part of decision ...

Read more →

Is innovation causing accessibility, timing issues for private drug plans?

17 January 2020 - Pharmaceutical companies and private payers can interact in different ways to ensure the right drugs are ...

Read more →

Closing the cycle of innovation in health care in Europe

17 January 2020 - Pragmatic or practice-oriented comparative effectiveness trials may be conducted to fill the evidence gaps that are revealed ...

Read more →

Pharmacare with no new medicines

10 December 2019 - Meeting with pricing officials shows that government's true goal is to slash prices so low that no ...

Read more →

Do large pharma companies provide drug development innovation? Our analysis says no.

10 December 2019 - Large pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. ...

Read more →

Proposed changes to research and development tax incentive will discourage investment and undermine innovation

6 December 2019 - Medicines Australia is disappointed that proposed changes to the Research and Development Tax Incentive were tabled ...

Read more →

White House claims Speaker Nancy Pelosi’s drug pricing bill would result in 100 fewer drugs over a decade

3 December 2019 - The report from the administration suggests far greater consequences for both the drug industry and American consumers ...

Read more →

Using GRADE methodology to assess innovation of new medicinal products in Italy

25 November 2019 - In April 2017 the Italian Medicine Agency developed new criteria to grant any new medicinal product with ...

Read more →

Pelosi’s drug pricing plan puts medical innovation at risk

17 October 2019 - The future of medical innovation in America is at a crossroads. ...

Read more →